Trial Profile
Phase II study of RPL 554 in patients with chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2013
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 10 Jul 2012 Status changed from not yet recruiting to completed, as reported by a Verona Pharma Annual Report (2011).
- 01 Feb 2011 New trial record